Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Open Access

Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSamantha I. LiangParker Institute for Cancer ImmunotherapyZQZoe QuandtUniversity of California, San FranciscoSWSara WienkeGuardant (United States)

Discussion

Loading...

Member takes

Implication

Forest plot analysis identifies tumor fraction change thresholds in patients receiving immune checkpoint inhibitors, suggesting potential clinical outcomes.

Key Points

  • Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors, indicating reliable prognosis.
  • Analysis revealed significant thresholds for tumor fraction changes, improving patient outcome assessments in cancer therapies.
  • Observational analysis using forest plot methodology assessed tumor fraction changes across a diverse cancer population.
  • Findings support ongoing monitoring for ctDNA levels as a potential marker for treatment efficacy across various cancers.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94fedddahttps://doi.org/10.1158/2767-9764.29948087
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  2. 2Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  3. 3Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  4. 4Supplementary Figure S1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  5. 5Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025